Proteomics Slated for Science Writers' Seminar
An update on clinical proteomics will be presented at the NCI Science Writers' Seminar on January 28, 2004.
These sessions are designed for science and medical reporters with the intent of increasing the quality and quantity of media coverage on cancer research. The speakers will be Dr. Lance Liotta and Dr. Emanuel Petricoin, codirectors of the NCI/Food and Drug Administration Clinical Proteomics Program, and their collaborator Dr. Elise Kohn, from the NCI Laboratory of Pathology.
The scientists will explain their successes in distinguishing ovarian, breast, and prostate cancers from benign conditions and how their techniques can be used to clinically identify early-stage cancers. They will highlight progress since their 2002 landmark paper in The Lancet, which first described proteomics for possible use in detecting ovarian cancer. The seminar will be held from 11 a.m. to 1:30 p.m. on the NIH campus in Bethesda at the Natcher Conference Center, Room F1. Pre-registration is required for on-site attendance, but anyone can watch the live webcast at http://videocast.nih.gov/.
President's Cancer Panel Focuses on Survivorship
The panel has heard of the difficulties all survivors endure: transferring NCI treatment records to their community providers, accessing relevant post-treatment information, obtaining appropriate follow-up screening and care, acquiring necessary support services, overcoming financial and insurance-related barriers, and addressing cultural and language barriers to care.
Specific issues affect survivors ages 60 and older. Survivors in this age group told the panel of the hardships of living on a fixed income. They also expressed their fears of losing their employment and associated insurance benefits. They called for improved communication with the public - employers, caregivers, and insurers - about the experiences and needs of cancer survivors.
Older adult survivors have more co-morbidity issues, which may obscure symptoms of recurrence. They metabolize pharmacologic agents differently than younger people. And they are more concerned about transmitting genetically linked cancers to their children.
The panel's final report on cancer survivorship is expected to be released this summer.
Sporn Named First NCI Eminent Scholar
Also at the retreat, Dr. Janet D. Rowley, University of Chicago, an expert on human chromosome analysis, accepted the Rosalind E. Franklin Award for Women in Cancer Research. Dr. Rowley, an Albert Lasker Award recipient, is internationally known for her discovery that the translocation of genetic material seen in the Philadelphia chromosome is the cause, not the result, of chronic myelogenous leukemia. The NCI prize honors the commitment of women in cancer research and is given in tribute to Dr. Franklin, who played a critical role in the discovery of the DNA double helix.